AABB Announces Research Selected for 2024 Annual Meeting Plenary Oral Abstract Session

AABB is pleased to announce the research selected for inclusion in the Plenary Oral Abstract Session at the 2024 AABB Annual Meeting, to be held Oct. 19-22 in Houston, Texas.

Every year, the Plenary Oral Abstract Session at the AABB Annual Meeting consists of the research deemed to be the most significant for the year in the field of blood and biotherapies. Among the hundreds of abstracts reviewed by the AABB Selection of Abstracts Committee, six have been honored this year with inclusion in the Plenary Oral Abstract Session. These abstracts have been chosen by the committee for their superior scientific merit and their potential influence on advancing the field.

“The Plenary Oral Abstract Session is always a highlight of the AABB Annual Meeting, featuring the most important research of the year,” said Melissa Cushing, MD, chair of the AABB Selection of Abstracts Committee. “This year’s session continues this tradition and will comprise six abstracts deemed to be the best of the year. This is the research that represents the highest scientific quality and is likely to have the most significant impact on our field. This year we will hear about the results of a major clinical trial investigating pathogen reduced red blood cells, two novel cellular biotherapy products, freeze-dried platelets to treat platelet refractory patients, mechanisms to regulate red cell alloimmunization, and the impact of the implementation of individual donor assessments in the United States. I encourage all attendees to make this session a priority in Houston. Many, if not all, of the abstracts discussed are likely to change clinical practice in the near future.”

The abstracts chosen for this year’s Plenary Oral Abstract Session are: 

• Acute Kidney Injury to Evaluate Amustaline/Glutathione Pathogen Reduced Red Cells in Cardiac Surgery: Outcomes of the ReCePI Phase III Clinical Trial, presented by Richard Benjamin, MD. 
• ADAMTS13-Chimeric Auto-Antigen Receptor T cells to Target Autoreactive B Cells as a Treatment for Immune-mediated Thrombotic Thrombocytopenic Purpura, presented by Roman H. Khadka, PhD. 
• Antioxidant Responses Regulate RBC Alloimmunization, presented by David R. Gibb, MD, PhD. 
• Freeze-Dried Platelets Decrease Bleeding in Refractory Thrombocytopenic Patients With Hematological Malignancies, presented by Maro Ohanian, DO. 
• Genetic Engineering of Megakaryocytes from Blood Progenitor Cells Using mRNA Lipid Nanoparticles, presented by Jerry Leung, PhD. 
• Implementation of Individual Donor Assessment in the USA and Impact on Rates of Residual Infectious Disease, presented by Mary Townsend, MD.

AABB congratulates the researchers whose abstracts were chosen for this year’s Plenary Oral Abstract Session and looks forward to seeing them present their findings in Houston.